Pharmaceutical Preparations · NYSE
For the period ended December 28, 2025, JOHNSON & JOHNSON reported $94.2 billion across 2 reportable segments: Innovative Medicine ($60.40B, 64.1%), Med Tech ($33.79B, 35.9%).
For the period ended December 28, 2025, JOHNSON & JOHNSON reported $94.2 billion across 4 geographies: United States ($53.75B, 57.1%), Europe ($21.54B, 22.9%), Asia-Pacific, Africa ($14.03B, 14.9%), Western Hemisphere, excluding U.S. ($4.88B, 5.2%). United States's share of the total is up from 51.3% for the period ended December 29, 2019.
JOHNSON & JOHNSON annual revenue by reportable segment, as disclosed in SEC filings.
| Segment | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| Innovative Medicine | $51.68B | $52.56B | $54.76B | $56.96B | $60.40B | 64.1% |
| Med Tech | $27.06B | $27.43B | $30.40B | $31.86B | $33.79B | 35.9% |
| Total | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
JOHNSON & JOHNSON annual revenue by geography, as disclosed in SEC filings.
| Region | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| United States | $40.64B | $41.98B | $46.44B | $50.30B | $53.75B | 57.1% |
| Europe | $20.59B | $20.66B | $20.41B | $20.21B | $21.54B | 22.9% |
| Asia-Pacific, Africa | $13.58B | $13.24B | $13.76B | $13.59B | $14.03B | 14.9% |
| Western Hemisphere, excluding U.S. | $3.93B | $4.11B | $4.55B | $4.71B | $4.88B | 5.2% |
| Total | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B |
Extracted from the XBRL segment tags in the company’s SEC filings. Figures are as reported and are not restated or adjusted.
Data: SEC EDGAR (financials, KPIs, segments) · Yahoo Finance (price, splits, metrics, analyst estimates, news headlines). Not financial advice.